Perrigo (PRGO) to Post Quarterly Earnings on Wednesday

Perrigo (NYSE:PRGO) is expected to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Perrigo to announce earnings of $0.39 per share and revenue of $1.0134 billion for the quarter. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the business posted $0.60 earnings per share. The firm’s revenue for the quarter was down 7.2% compared to the same quarter last year. On average, analysts expect Perrigo to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Perrigo Stock Up 0.4%

Shares of NYSE:PRGO opened at $10.34 on Wednesday. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -0.78, a PEG ratio of 1.20 and a beta of 0.51. The stock’s 50-day moving average price is $10.59 and its two-hundred day moving average price is $11.71. Perrigo has a 12-month low of $9.23 and a 12-month high of $28.22.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.33.

Institutional Investors Weigh In On Perrigo

Institutional investors have recently added to or reduced their stakes in the company. Amundi raised its holdings in shares of Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after purchasing an additional 556 shares during the period. Kestra Investment Management LLC increased its position in Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares during the period. UMB Bank n.a. lifted its position in Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after buying an additional 1,213 shares in the last quarter. Finally, M&T Bank Corp grew its stake in Perrigo by 20.5% during the second quarter. M&T Bank Corp now owns 7,956 shares of the company’s stock worth $213,000 after buying an additional 1,354 shares during the period. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.